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Abstract
Alzheimer’s disease is the most common cause of dementia. According to the amyloid 
hypothesis, β-secretase (BACE1) is a promising molecular target for the development 
of anti-Alzheimer’s disease drugs. BACE1 triggers the formation of the amyloid-β (Aβ) 
peptides that are the main component of senile plaques in the brain of patients with 
Alzheimer’s disease. As BACE1 cleaves the amyloid precursor protein at the N-terminus 
of the Aβ domain, BACE1 inhibitors reduce the Aβ level in the brain. Previously, we 
designed a series of peptidic inhibitors that possessed a substrate transition-state analogue, 
and the structure-activity relationship of our inhibitors was evaluated, based on docking 
and scoring, using the docking simulation software Molecular Operating Environment 
(MOE). However, there was no association between the scoring values and the inhibitory 
activities at the P
2
 position. Hence, we hypothesized that the interaction of the P
2
 position 
of the inhibitor with the S
2
 site of BACE1 was critical for the mechanism of inhibition, and 
we proposed the novel concept of ‘electron donor bioisostere’ for drug discovery. Using 
this concept, we designed potent small molecule non-peptidic BACE1 inhibitors.
Keywords: Alzheimer’s disease, BACE1 inhibitor, docking simulation, electron donor 
bioisostere, in-silico conformational structure-based design
1. Introduction
Alzheimer’s disease (AD), which is the most common cause of dementia, is characterized by pro-
gressive intellectual deterioration. In 1901, Alois Alzheimer, a psychiatrist and neuropathologist, 
observed a 51-year-old female patient at Frankfurt Asylum. The patient showed strange behav-
ioural symptoms and the loss of short-term memory, which was later called ‘AD’. Unfortunately, 
the cause of AD was unclear until recently, and there have been no treatment approaches since 
that first report by Dr. Alzheimer over 100 years ago. Recently, the development of many drug 
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candidates based on the amyloid hypothesis has been reported. β-secretase (BACE1; β-site amy-
loid precursor protein (APP) cleaving enzyme 1) is a promising molecular target for the devel-
opment of anti-Alzheimer’s drugs. BACE1 triggers the formation of the amyloid-β (Aβ) peptide 
that is the main component of the senile plaques found in the brain of AD patients. Previously, 
we had designed a series of peptidic inhibitors that possessed a substrate transition-state ana-
logue, and evaluated the structure-activity relationship of our inhibitors, based on docking and 
scoring, using the docking simulation software Molecular Operating Environment ((MOE), 
Chemical Computing Group Inc., Canada).
1.1. Pathology of Alzheimer’s disease
Although the cause of AD was unclear until recently, a breakthrough was obtained from the 
genetic study of some patients with familial AD. Certain mutations of the amyloid precur-
sor protein (APP) or presenilin gene increased amyloid-β peptides (Aβs) in the brain, which 
indicated their involvement in the pathogenesis of AD [1–4]. Aβ is produced from APP by two 
processing enzymes, β-secretase and γ-secretase, which are potential molecular targets for the 
development of anti-AD drugs [5–7]. The cleavage sites of APP are shown in Figure 1A. BACE1, 
one of the processing enzymes of APP, triggers Aβ formation in the rate-limiting first step by 
the cleavage of APP at the Aβ domain N-terminus (β-site). BACE1 is a type-I  transmembrane 
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Figure 1. (A) Amyloid precursor protein (APP) and its cleavage site. (B) Early peptidic BACE1 inhibitor by Ghosh et al.
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aspartic protease with 501 amino acids. BACE1 and APP are located in the same intracellular 
granules, the endoplasmic reticulum, Golgi, and trans-Golgi networks, which are acidic envi-
ronments, which suggested that Aβs are produced in these locations [8]. Next, another aspar-
tic protease, the γ-secretase complex, cleaved at the C-terminus of the Aβ domain and released 
Aβ peptides. The γ-secretase complex that contains a protein via the presenilin gene as a cata-
lytic component cleaved at two cleavage sites, ‘γ-sites’, which mainly resulted in the formation 
of two species of Aβs: Aβ1-40 and Aβ1-42 (Figure 1A). Aβ1-42 shows greater neurotoxicity and aggregability than Aβ1-40 and appears to be a key biomolecular marker of AD pathogenesis. According to the amyloid hypothesis, BACE1 and γ-secretase appear to be molecular targets 
for the development of anti-AD drugs. However, because γ-secretase can cleave other single-
pass transmembrane proteins in vivo, such as Notch, which plays a critical role in cell differ-
entiation, γ-secretase inhibitors appeared to lead to serious side effects. As BACE1 knockout 
transgenic mice demonstrated normal survival, this indicated a promising direction of study, 
in which BACE1 is a molecular target for the development of AD drugs [9]. At present, many 
BACE1 inhibitors have been revealed, including those in our study [10–16].
1.2. Early peptidic BACE1 inhibitors
An early inhibitor of BACE1, an aspartic protease, was designed on the basis of a substrate 
transition-state concept, as well as that of other aspartic proteases, such as renin and HIV 
protease, which have a substrate transition-state analogue at the P1 position [10–16]. It is well-known that the Swedish mutant APP (K670N and M671L double mutation, Figure 1A) is 
cleaved faster than wild-type APP by BACE1, which results in increased Aβ1-42 and Aβ1-40 levels. Early BACE1 inhibitors were designed based on the Swedish-mutant APP amino acid 
sequence. In 1999, Sinha et al. from Elan Pharmaceuticals purified the BACE1 enzyme from 
the human brain using a transition-state analogue based on the Swedish-mutant sequence, 
and succeeded in cloning the BACE1 enzyme [17]. Ghosh et al. reported the potent inhibitors 
OM99-2 (Ki = 1.6 nM) and OM00-3 (Ki = 0.3 nM) with a hydroxyethylene unit as a substrate 
transition-state analogue (Figure 1B) and the first X-ray crystal structure (PDB ID: 1FKN) of a 
complex between recombinant BACE1 and OM99-2 [18–21].
We have reported a series of peptidic BACE1 inhibitors that possessed a norstatine-type tran-
sition-state analogue [22–30]. Our early inhibitors are shown in Table 1. Octapeptide 1 with an 
Asn residue and (2R, 3S)-3 amino-2-hydroxy-5-methylhexanoic acid (Nst, Leu-type transition-
state analogue) at the P
2
 and P1 positions, respectively, corresponding to the Swedish-mutant APP sequence showed no inhibitory activity. Octapeptide 2 with (2R, 3S)-3-amino-2-hydroxy-
4-phenylbutyric acid (Pns) as a transition-state analogue at the P1 position, showed weak inhib-itory activity. Compound 3 with an Asp residue similar to OM00-3, and compound 4, with a 
Met residue at the P
2
 position, also showed weak inhibitory activity. Although compound 5 
with the P
2
-Lys residue that corresponded to the wild-type APP sequence showed no inhibitory 
activity, octapeptide 6 that possessed a Leu residue at the P
2
 position exhibited potent inhibi-
tory activity (>90% at 2 μM). We synthesized some truncated peptides on the N- or C-terminus 
in order to confirm the essential moiety for the inhibitory effect. N-truncation of peptides elimi-
nated their inhibitory activity (peptides 7-8). Although C-truncated peptides 10-13 showed a 
weaker inhibitory activity than octapeptide 6, pentapeptide 12 replicated the inhibitory activity 
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of heptapeptide 10. Hence, we designed a series of pentapeptidic BACE1 inhibitors based on 
compound 12 using a computational approach.
2. Docking simulation and design of pentapeptidic BACE1 inhibitors
Early BACE1 inhibitors were designed using the coordinates of the first reported X-ray 
crystal structure (1FKN) of a complex between BACE1 and OM99-2. OM99-2 has an Asn 
residue, which corresponded to the P
2
 residue of Swedish mutant sequence. As OM99-2 in 
1FKN appeared to interact with the BACE1-Arg235 side chain via hydrogen bonding, many 
researchers have designed BACE1 inhibitors that possessed a hydrogen bond receptor, such 
as an Asn residue, at the P
2
 position, using the 1FKN coordinates. However, our peptidic 
BACE1 inhibitors with an Asn at the P
2
 position showed no inhibitory activity, and, as shown 
in Table 1, the P
2
 residue that showed potent BACE1 inhibitory activity was a hydrophobic 
amino acid residue, Leu. Thus, our design strategy seemed to require a fundamental review. 
We researched the inhibitory mechanism of our peptides using a computational approach. 
As we found that pentapeptide 21, which possessed an aminobenzoic acid residue as a bio-
isostere of the Asp residue at the P1’ position, showed higher inhibitory activity than penta-
peptide 12, we evaluated the series of pentapeptides 14-24 with an aminobenzoic acid residue 
by using a docking simulation, and then synthesized the compounds (Table 2). The docking 
Compound P
4
P
3
P
2
P
1
P
1
’ P
2
’ P
3
’ P
4
’ BACE1 
inhibition 
(%)1
1 E V N2 Nst D A E F <20
2 E V N2 Pns D A E F 24
3 E V D Pns D A E F 25
4 E V M Pns D A E F 42
5 E V K3 Pns D A E F <20
6 E V L Pns D A E F >90
7 V L Pns D A E F <20
8 L Pns D A E F <20
9 Pns D A E F <20
10 E V L Pns D A E 60
11 E V L Pns D A 46
12 E V L Pns D 61
13 E V L Pns 34
1BACE1 inhibition activities at 2 μM.
2P
2
 residue corresponding to the Swedish-mutant APP sequence.
3P
2
 residue corresponding to the wild-type APP sequence.
Table 1. BACE1 inhibitory activities of peptidic BACE1 inhibitors.
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simulation was performed using MOE software under the MMFF94x force field. The calcu-
lated active sites of BACE1 were depicted in Figure 2A using the Alpha SiteFinder application 
in MOE software and the coordinate set of X-ray crystal structure, 1FKN. The 3D structure of 
OM99-2 after a docking simulation is shown in Figure 2B as a magenta-coloured stick model. 
Because the moieties from the P1 to P4 positions of OM99-2 almost coincided with that of the X-ray crystal structure (aqua coloured stick model) of OM99-2, we performed the docking 
simulation study using this calculation model. Although the moieties from the P
2
’ to P
4
’ posi-
tions of OM99-2 assumed a different pose from that of the X-ray crystal structure of OM99-2, 
their moieties were placed outside the BACE1 enzyme. It is likely that the difference between 
the X-ray crystal structure and the docking calculation might occur by a packing at the crys-
tallization of BACE1 complex. The results of the docking simulation are shown in Table 2. 
Peptides 14-24 and OM99-2 were scored using the scoring function in the MOE software. 
Compound Xaa U_ele1 U_vdw2 U_str3 U_dock4 BACE1 
inhibition (%)5
OM99-2 (see Figure 1) −284.7 28.0 14.6 −242.1 —
14 N −184.4 4.2 10.2 −170.0 28.4
15 M −196.1 14.8 11.4 −169.9 63.9
16 Y −195.2 18.5 13.6 −163.1 36.9
17 D −174.1 2.0 11.2 −160.9 33.2
18 I −196.3 25.7 11.1 −159.5 65.8
19 F −176.8 9.0 11.6 −156.2 47.3
20 E −179.8 11.9 22.3 −145.6 36.3
21 L −155.1 3.3 10.2 −141.6 83.7
22 W −187.1 19.6 26.6 −140.9 71.3
23 Q −148.9 −0.3 9.8 −139.4 14.1
24 Cha6 −147.1 −1.2 9.7 −138.6 84.1
1Electrostatic energy between BACE1 and inhibitor (kcal/mol).
2van der Waals energy between BACE1 and inhibitor (kcal/mol).
3Strain energy of inhibitor (kcal/mol).
4Docking score (kcal/mol); U_dock = U_ele + U_vdw + U_str.
5BACE1 inhibition % at 2 μM.
6Cyclohexylalanine (Cha).
Table 2. Docking simulation of pentapeptidic BACE1 inhibitors and their score using the 1FKN X-ray crystal structure.
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U_ele, U_vdw, and U_str indicated the potential energies of electrostatic interaction, van der 
Waals interactions between enzyme and ligand, and strain energy of the ligand, respectively, 
and their sum is a docking score, U_dock. OM99-2 and peptide 14, which possess an Asn 
residue at the P
2
 position, showed good scores. However, peptides 14 and 17, that possess a 
hydrophilic amino acid, such as Asn and Asp, showed a low inhibitory activity. The residues 
of peptides 21 and 24 that exhibited a high inhibitory activity were hydrophobic amino acids 
such as Leu and cyclohexylalanine (Cha), as well as the results in Table 1. Interestingly, pep-
tides 21 and 24 showed low scores. Thus, there was no association between the scoring values 
and the inhibitory activity at the P
2
 position.
As the docking model using the coordinate set of 1FKN appeared to give an unfavourable 
score for the BACE1 inhibitor, we compared the publicly available X-ray crystal structures 
of BACE1-inhibitor complexes. Surprisingly, the guanidine group of BACE1-Arg235 in most 
Figure 2. (A) Calculated active sites using the Alpha Site Finder application in MOE software. (B) OM99-2 docked in 
BACE1. Aqua and magenta colours indicate the X-ray crystal structure 1FKN and the energy-minimized structure under 
the MMFF94x force field, respectively.
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crystal structures, except 1FKN, showed similar figures flopping over the P
2
 region of the 
inhibitors, and the nearest distances between the guanidino-plane of Arg235 side chain and 
the P
2
 region of the inhibitor showed similar values of approximately 3Å [31]. The P
2
 moieties 
in most of the crystal structures found to interact with the BACE1-Arg235 side chain were a 
methyl group, carbonyl oxygen atom, or aromatic ring, which were bound to the guanidine-
plane of Arg235 side chain by CH-π, O-π, or π-π stacking interactions. This suggested that 
the π-orbital on the guanidino-plane interacted with the P
2
 region by a weak quantum force 
such as stacking or σ-π interaction. The only exception was the interaction in the first reported 
X-ray crystal structure, 1FKN. The P
2
 moiety of OM99-2 in the crystal structure 1FKN appeared 
to interact with the BACE1-Arg235 side chain via hydrogen bonding (Figure 3A). OM00-3, 
which was reported by the same researchers, was an inhibitor that was structurally similar 
to OM99-2; surprisingly, the P
2
-Asp side chain of OM00-3 docked in BACE1 (PDB ID: 1M4H) 
interacted with the π-orbital on the guanidine-plane of the BACE1-Arg235 side chain via O-π 
interaction (Figure 3B). Many early BACE1 inhibitors that possess a hydrogen bond receptor 
at the P
2
 position were designed using the first reported crystal structure 1FKN. However, 
the hydrogen bonding interaction between most of the inhibitors and the BACE1-Arg235 side 
chain was not shown in their crystal structures. For instance, the inhibitor from Merck (MSD), 
crystal structure (PDB ID: 2B8L), interacted with the BACE1-Arg235 side chain via a CH-π 
interaction (Figure 3C). The researchers at MSD most likely based their inhibitor on a structure 
that possessed an N-methyl-N-methanesulfonyl group at the P
2
 position in anticipation of the 
hydrogen-bonding interaction between the sulfonyl oxygen atom and the BACE1-Arg235 side 
chain. However, the N-methyl group of the MSD inhibitor interacted with the π-orbital on the 
guanidine-plane of the BACE1-Arg235 side chain at a distance of 2.8 Å. The inhibitor reported 
by Pfizer (PDB ID: 2P83) appeared to interact with the BACE1-Arg235 side chain via O-π inter-
actions, as shown in Figure 3D. As seen above, most of the BACE1 inhibitors, except OM99-2 in 
the crystal structure 1FKN, interacted with the BACE1-Arg235 side chain by a weak quantum 
force such as stacking or σ-π interaction. The Arg235 side chain of the BACE1-OM99-2 com-
plex (1FKN) assumed an exceptionally different pose to the other crystal structures because 
the BACE1 complex appears to be stabilized by intramolecular hydrogen-bonding interaction 
between the P
4
-Glu and P
2
-Asn side chains of OM99-2 (Figure 3A). Because OM00-3 does not 
form such intramolecular hydrogen-bonding, the P
2
 residue of OM00-3 appears to interact with 
the BACE1-Arg235 side chain by a quantum chemical interaction. As many researchers have 
designed BACE1 inhibitors with a hydrogen bond receptor on the basis of the first reported 
crystal structure 1FKN, docking models using 1FKN will require further review. Furthermore, 
we found that the side chain of BACE1-Arg235 could move in concert with the inhibitor’s size. 
The superimposed figure of four crystal structures (PDB ID: 2B8L, 1M4H, 1W51, and 2IQG) of 
the complex between BACE1 and the inhibitors is depicted in Figure 4. The guanidino-planes 
of BACE1-Arg235 in the crystal structures of most BACE1 complexes showed similar distances 
from the P
2
 regions of the inhibitors regardless of their molecular size [31]. This fact suggested 
a serious issue for a docking simulation for the drug discovery of BACE1 inhibitors. However, 
the BACE1-Arg235 side chain seems to have a restricted range of motion: the BACE1-Arg235 
side chain slides sideways, not up and down, along the wall of the β-sheet structure that con-
sists of four peptide strands behind the flap domain of BACE1; therefore, the location of the 
BACE1-Arg235 side chain could be predicted by the inhibitor’s size. As shown in Figure 4, the 
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Figure 4. Location of BACE1-Arg235 in the respective crystal structures. The blue, magenta, green and red stick models 
represent the X-ray crystal structures of the BACE1-inhibitor complexes, 2B8L, 1M4H, 1W51 and 2IQG, respectively.
Figure 3. Interaction of BACE1-Arg235 with BACE1 inhibitors in X-ray crystal structures. (A) PDB ID: 1FKN, (B) PDB ID: 
1M4H, (C) PDB ID: 2B8L and (D) PDB ID: 2P83.
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orbital follows the same pattern along the wall of the β-sheet structure of BACE1 and might 
be predicted according to the inhibitor’s size. We hypothesized that the role of the BACE1-
Arg235 side chain was important for the BACE1 inhibitory mechanism. The guanidine-plane 
of Arg235 that can move in concert with the inhibitor’s size appears to push down on the P
2
 
region of the inhibitor, which caused them to be affixed to the active site of BACE1 because of 
this ‘flop-over’ mechanism by the BACE1-Arg235 side chain. Although a quantum chemical 
force, such as σ-π interaction, has a weaker binding energy than a hydrogen bonding interac-
tion, this ‘flop-over’ mechanism permits a strong binding mode with the active site of BACE1.
For the reasons mentioned above, we performed a docking calculation using the X-ray crystal 
structure 1M4H, in which the P
2
 moiety of the inhibitor (OM00-3) had a similar size to that of 
our inhibitor (Table 3). OM00-3 appears to show a high docking score value owing to its large 
molecular size: OM00-3 has many more amide bonds than our peptapeptidic inhibitors, and 
Compound Xaa U_ele1 U_vdw2 U_str3 U_dock4 BACE1 
inhibition (%)5
OM00-3 (see Figure 1) −233.4 0.7 15.7 −217.0 —
21 L −195.7 11.3 10.3 −174.1 83.7
22 W −189.3 13.0 10.5 −165.8 71.3
18 I −194.6 18.5 11.1 −165.0 65.8
19 F −195.6 23.0 11.7 −160.9 47.3
15 M −195.6 24.6 10.1 −160.9 63.9
24 Cha6 −194.4 26.6 11.6 −156.2 84.1
16 Y −196.7 26.5 14.1 −156.1 36.9
20 E −190.7 24.2 10.6 −155.9 36.3
14 N −190.7 24.2 11.3 −155.2 28.4
23 Q −196.9 27.6 15.7 −153.6 14.1
17 D −185.5 28.5 9.7 −147.3 33.2
1Electrostatic energy between BACE1 and inhibitor (kcal/mol).
2van der Waals energy between BACE1 and inhibitor (kcal/mol).
3Strain energy of inhibitor (kcal/mol).
4Docking score (kcal/mol); U_dock = U_ele + U_vdw + U_str.
5BACE1 inhibition % at 2 μM.
6Cyclohexylalanine (Cha).
Table 3. Docking simulation of pentapeptidic BACE1 inhibitors and their scoring using the 1M4H X-ray crystal structure.
Discovery of BACE1 Inhibitors for the Treatment of Alzheimer’s Disease
http://dx.doi.org/10.5772/intechopen.68659
35
can closely interact with the BACE1 active site via electrostatic energy. The correlation chart 
between BACE1 inhibitory activities and the docking score values is shown in Figure 5, and it 
indicated a good correlation coefficient (r = −0.717). Peptides that possess a hydrophilic amino 
acid residue at the P
2
 position showed low docking score values, which indicated that these 
P
2
 residues cannot interact with the BACE1-Arg235 side chain via electrostatic energy in the 
X-ray crystal structure 1M4H, and the docking score showed a good correlation with BACE1 
inhibitory activity as a result. However, the plot of peptide 24 was outside of the correlation 
line. Peptide 24, with the bulky amino acid Cha at the P
2
 position, might show van der Waals 
repulsion against the BACE1-Arg235 side chain.
Furthermore, we designed a series of BACE1 inhibitors that possessed one or more bioisosteres 
of carboxylic acid from pentapeptide 21 that conferred excellent values to both docking score and 
BACE1 inhibitory activity, in order to develop practical BACE1 inhibitors as drug candidates 
(Figure 6). A tetrazole ring is known as a carboxylic bioisostere. Because it is well known that 
5-aminotetrazole was highly explosive, peptides 25 and 26, which possessed a carboxylic acid 
bioisostere at the P
4
 position were designed and synthesized using tetrazole-5-carboxylic acid. 
Peptides 25 and 26 showed potent BACE1 inhibitory activities (IC50 = 8.2 nM and 3.9 nM, respec-tively) [24, 25]. Moreover, peptide 27, which possessed two tetrazole rings on the P1’ ring, was synthesized. Peptide 27 showed the most potent BACE1 inhibitory activity (IC50 = 1.2 nM) [26].
Figure 5. The correlation between BACE1 inhibitory activities and the docking score values.
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3. Design of small-sized non-peptidic BACE1 inhibitors
At present, many non-peptidic BACE1 inhibitors have been discovered. The research of Elan 
pharmaceuticals, Merck (MSD), Pfizer, and Schering-Plough, and Ghosh et al. reported the 
BACE1 inhibitors 28-32 (IC50 = 15, 15, 5, 3, and 1 nM, respectively) with an isophthalic scaffold at the P
2
 position, as shown in Figure 7 [14, 16]. Because the distance between the flap domain and 
the cleft domain that forms the S
2
 pocket of BACE1 was narrow, a planar aromatic ring, such 
as an isophthalic scaffold, might dock closely in the S
2
 pocket of BACE1. Hence, we designed 
a series of BACE1 inhibitors from the virtual inhibitor 28 (Figure 8), in which the P
2
 moiety of 
our peptidic inhibitors was replaced with an isophthalic scaffold [31–35]. First, we focused on 
the sterically hindered interaction between the P3 amide and a proton on the P2-isophthalic ring of the virtual inhibitor, which restricts the configuration. Using the approach ‘in-silico confor-
mational structure-based design’ based on a conformer of the docked inhibitor in BACE1, we 
adopted a pyridinedicarboxylic scaffold as a P
2
 moiety, which lacked the 2-proton from the 
isophthalic ring, and designed inhibitor 29 [32]. Next, we optimized the P3-region of inhibitor 29 
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Figure 6. Design of practical BACE1 inhibitors using a carboxylic acid bioisostere.
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Figure 7. BACE1 inhibitors with an isophthalic scaffold.
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Figure 8. Design of small-sized non-peptidic BACE1 inhibitors with a 2,6-pyridinedicarboxylic scaffold.
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with a P
2
-pyridinedicarboxylic scaffold. There is a S3 sub-pocket behind the active site of BACE1, and the P3 phenyl group of 29 appears to interact with the S3 sub-pocket. We envisioned that inhibitors with a P3 benzylamide group assumed a folding pose between the P2 aromatic scaf-fold and the P3 benzylamide, and that the α-methyl group on the P3 benzylamide of 29 stabilized this folding structure. Hence, we designed inhibitor 30 by the introduction of a five-membered 
ring, oxazolidine, at the P3 region to fix the folding structure [32]. The oxazolidine ring fixes the direction of the phenyl ring at the P3 position, so that the P3 phenyl ring may be able to bind 
closely to the S3 sub-pocket of BACE1. Inhibitor 30 showed moderate BACE1 inhibitory activity (IC50 = 140 nM).
Although in-silico approaches, such as a docking simulation between an enzyme/receptor and 
drugs, have contributed greatly to drug discovery research, most docking simulation software 
programs adopt molecular mechanics/molecular dynamics (MM/MD) calculations based on 
classical Newtonian mechanics. However, docking simulations using these calculations do 
not appear to estimate weak quantum chemical interactions, such as stacking or σ-π interac-
tion, between the BACE1-Arg235 side chain and inhibitors. Because the Arg residue is rec-
ognized as charged in these software programs, the quantum chemical interactions involving 
an Arg side chain are unlikely to receive a favourable score. The concept of ‘bioisostere’ is 
important for the development of practical drugs. However, in the case of BACE1 inhibitor 
design, the bioisostere of the P
2
 moiety, according to the Swedish-mutant APP, is an Asn or an 
amide residue based on a classical bioisostere concept that does not assume quantum chemical 
interactions. Therefore, inhibitors that can interact with the Arg235 side chain on the basis 
of a quantum chemical interaction could never be designed using such a classical concept. 
The researchers at Bristol-Myers Squibb (BMS) reported a series of BACE1 inhibitors that can 
interact with the BACE1-Arg235 side chain by π-π stacking. According to their SAR study, 
the introduction of an electron-donating methoxy group to the p-position of the phenyl ring 
that interacts with the BACE1-Arg235 side chain enhanced BACE1 inhibitory activity. This 
indicated that an inhibitor that possessed a P
2
 aromatic ring with higher electron density could 
strongly dock to the active site of BACE1 that has an electron-poor π-orbital on the guanidino-
plane of the BACE1-Arg235 side chain. Hence, we proposed a new concept of the ‘electron-
donor bioisostere’, which can interact with an electron-poor π-orbital, such as the guanidine 
group of Arg235, by quantum chemical interactions [14].
Based on the electron-donor bioisostere concept, we speculated that an electron-rich halo-
gen atom could interact with the electron-poor guanidine π-orbital by Coulomb interaction. 
Using the ab initio molecular orbital approach, Imai et al. indicated that the calculated Cl-π 
interaction energy was slightly stronger than that of CH-π interaction, and its energy was 
affected by π-electron density [36]. Inhibitor 31, which possessed a halogen atom on the P
2
 
aromatic scaffold, exhibited potent inhibitory activity (IC50 = 15 nM). Moreover, inhibitor 
32, which possessed a fluorine atom on the p-position of the P3 phenyl group exhibited the most potent inhibitory activity (IC50 = 9 nM), and was available from Wako Pure Chemical Industries (Japan) as a reagent for biological research [31]. The drastic improvement in the 
inhibition of BACE1 following the introduction of a halogen atom into the P
2
 position of our 
compounds appears to support our hypothesis; namely, the quantum chemical interactions 
between BACE1 and its inhibitors play a critical role in the mechanism of BACE1 inhibition.
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4. Conclusion
Although we calculated the docking scoring values by a docking calculation between 
BACE1 and its inhibitors using the first reported X-ray crystal structure 1FKN, we found no 
association between the scoring values and BACE1 inhibition. We found that a specific inter-
action, a quantum chemical interaction between the Arg235 side chain and the P
2
 region of 
the inhibitor, played a critical role in the inhibitory mechanism of BACE1. Whereas most 
BACE1 inhibitors, except OM99-2, interacted with BACE1-Arg235 by a quantum chemi-
cal interaction, such as stacking and σ-π interaction, many early BACE1 inhibitors were 
designed using the 1FKN coordinate set. As the crystal structure 1FKN showed a hydrogen 
bonding between the BACE1-Arg235 side chain and OM99-2, the early studies on BACE1 
inhibitor design might have misdirected, as a docking simulation using 1FKN appears to 
be meaningless. In fact, unlike 1FKN, there is no hydrogen bonding interaction present in 
most of the X-ray crystal structures. We selected the peptide sequence that showed potent 
inhibitory activity by a docking simulation using the X-ray crystal structure 1M4H, and 
designed potent peptidic BACE1 inhibitors with one or more carboxylic acid bioisosteres. 
Moreover, we focused on a quantum chemical interaction, and designed the potent non-
peptidic BACE1 inhibitor 32 using the ‘electron-donor bioisostere concept’ that we have 
proposed. Our findings indicated the importance of the X-ray crystal structure in computa-
tional drug design.
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